Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window?

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Talan, Mark I ^a   Ahmet, Ismayil ^a   Lakatta, Edward G ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ACUTE MYOCARDIAL INFARCT SIZE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY LIGATION; CORONARY REPERFUSION; DRUG EFFICACY; EXPERIMENTAL MODEL; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HISTOPATHOLOGY; MALE; NONHUMAN; RAT; RISK REDUCTION;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; ERYTHROPOIETIN; HUMANS; MALE; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; TIME FACTORS; TREATMENT FAILURE;

EID: 84860010915     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034819     Document Type: Article

References (25)

1. Bogoyevitch MA, (2004) An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 63: 208-216.
2. Koul D, Dhar S, Chen-Scarabelli C, Guglin M, Scarabelli TM, (2007) Erythropoietin: new horizon in cardiovascular medicine. Recent Pat Cardiovasc Drug Discov 2: 5-12.
3. Riksen NP, Hausenloy DJ, Yellon DM, (2008) Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 29: 258-267.
4. Latini R, Brines M, Fiordaliso F, (2008) Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev 13: 415-423.
5. Vogiatzi G, Briasoulis A, Tousoulis D, Papageorgiou N, Stefanadis C, (2010) Is there a role for erythropoietin in cardiovascular disease? Expert Opin Biol Ther 10: 251-264.
6. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, et al. (2006) Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 48: 2161-2167.
7. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, et al. (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20: 135-141.
8. Liem A, van de Woestijne AP, Bruijns E, Roeters van Lennep HW, de Boo JA, et al. (2009) Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol 131: 285-287.
9. Binbrek AS, Mittal B, Rao KN, Sobel BE, (2007) The potential of erythropoietin for conferring cardioprotection complementing reperfusion. Coron Artery Dis 18: 583-585.
10. Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE, (2009) Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol 104: 1035-1040.
11. Ozawa T, Toba K, Suzuki H, Kato K, Iso Y, et al. (2010) Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction- randomized controlled pilot trial of EPO/AMI-1 study. Circ J 74: 1415-1423.
12. Yoshimura N, Toba K, Ozawa T, Aizawa Y, Hosoya T, (2010) A novel program to accurately quantify infarction volume by (99 m)Tc MIBI SPECT, and its application for re-analyzing the effect of erythropoietin administration in patients with acute myocardial infarction. Circ J 74: 2741-2743.
13. Belonje AM, Voors AA, van Gilst WH, Anker SD, Slart RH, et al. (2008) Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J 155: 817-822.
14. Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, et al. (2010) A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 31: 2593-2600.
15. Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, et al. (2010) Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 3: 408-413.
16. Taniguchi N, Nakamura T, Sawada T, Matsubara K, Furukawa K, et al. (2010) Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 74: 2365-2371.
17. Melloni C, Rao SV, Povsic TJ, Melton L, Kim RJ, et al. (2010) Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J 160: 795-803.
18. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, et al. (2011) Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 305: 1863-1872.
19. Ferrario M, Arbustini E, Massa M, Rosti V, Marziliano N, et al. (2011) High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomized, placebo-controlled study. Int J Cardiol 147: 124-131.
20. Bhatt DL, (2011) Evaluation of agents to reduce infarct size; It can be quite REVEALing. JAMA 305: 1908-1909, (editorial).
21. Ahmet I, Wan R, Mattson MP, Lakatta EG, Talan MI, (2005) Cardioprotection by intermittent fasting in rats. Circulation 112: 3115-3121.
22. Ahmet I, Tae HJ, de Cabo R, Lakatta EG, Talan MI, (2011) Effects of calorie restriction on cardioprotection and cardiovascular health. J Mol Cell Cardiol 51: 263-271.
23. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI, (2005) Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther 19: 243-250.
24. Hirata A, Minamino T, Asanuma H, Fujita M, Wakeno M, et al. (2006) Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 48: 176-184.
25. Gibson CM, Pride YB, Frederick PD, Pollack CV Jr, Canto JG, et al. (2008) Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 156: 1035-44.